Annual SG&A
$52.87 M
+$6.80 M+14.76%
31 December 2023
Summary:
Arcturus Therapeutics Holdings annual selling, general & administrative expenses is currently $52.87 million, with the most recent change of +$6.80 million (+14.76%) on 31 December 2023. During the last 3 years, it has risen by +$29.65 million (+127.73%). ARCT annual SG&A is now at all-time high.ARCT Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$13.28 M
+$960.00 K+7.79%
30 September 2024
Summary:
Arcturus Therapeutics Holdings quarterly selling, general & administrative expenses is currently $13.28 million, with the most recent change of +$960.00 thousand (+7.79%) on 30 September 2024. Over the past year, it has dropped by -$101.00 thousand (-0.76%). ARCT quarterly SG&A is now -10.61% below its all-time high of $14.85 million, reached on 31 March 2024.ARCT Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.59 B
-$62.64 M-4.09%
30 September 2024
Summary:
Arcturus Therapeutics Holdings TTM selling, general & administrative expenses is currently -$1.59 billion, with the most recent change of -$62.64 million (-4.09%) on 30 September 2024. Over the past year, it has dropped by -$1.65 billion (-3150.80%). ARCT TTM SG&A is now -19363.11% below its all-time high of $53.96 million, reached on 31 March 2024.ARCT TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARCT Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.8% | -0.8% | -3150.8% |
| 3 y3 years | +127.7% | +22.3% | -4115.4% |
| 5 y5 years | +156.9% | +242.1% | -10000.0% |
ARCT Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +127.7% | -10.6% | +23.7% | -75.6% | +1.8% |
| 5 y | 5 years | at high | +317.6% | -10.6% | +641.3% | -653.8% | +1.8% |
| alltime | all time | at high | +7641.0% | -10.6% | +1314.6% | <-9999.0% | +1.8% |
Arcturus Therapeutics Holdings Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $13.28 M(+7.8%) | $52.95 M(-0.2%) |
| June 2024 | - | $12.32 M(-17.1%) | $53.05 M(-1.7%) |
| Mar 2024 | - | $14.85 M(+18.7%) | $53.96 M(+2.1%) |
| Dec 2023 | $52.87 M(+14.8%) | $12.51 M(-6.5%) | $52.87 M(+1.2%) |
| Sept 2023 | - | $13.38 M(+1.1%) | $52.22 M(+1.7%) |
| June 2023 | - | $13.22 M(-3.9%) | $51.34 M(+4.5%) |
| Mar 2023 | - | $13.76 M(+16.0%) | $49.10 M(+6.6%) |
| Dec 2022 | $46.07 M(+11.1%) | $11.86 M(-5.0%) | $46.07 M(+2.3%) |
| Sept 2022 | - | $12.49 M(+13.6%) | $45.02 M(+3.8%) |
| June 2022 | - | $10.99 M(+2.5%) | $43.39 M(+2.2%) |
| Mar 2022 | - | $10.73 M(-0.7%) | $42.44 M(+2.4%) |
| Dec 2021 | $41.45 M(+78.5%) | $10.81 M(-0.5%) | $41.45 M(+4.5%) |
| Sept 2021 | - | $10.86 M(+8.1%) | $39.68 M(+15.4%) |
| June 2021 | - | $10.04 M(+3.1%) | $34.39 M(+19.5%) |
| Mar 2021 | - | $9.74 M(+7.8%) | $28.77 M(+23.9%) |
| Dec 2020 | $23.22 M(+83.4%) | $9.03 M(+62.1%) | $23.22 M(+45.3%) |
| Sept 2020 | - | $5.57 M(+26.1%) | $15.97 M(+11.8%) |
| June 2020 | - | $4.42 M(+5.5%) | $14.28 M(+7.2%) |
| Mar 2020 | - | $4.19 M(+134.0%) | $13.32 M(+5.2%) |
| Dec 2019 | $12.66 M(-38.5%) | $1.79 M(-53.9%) | $12.66 M(-11.5%) |
| Sept 2019 | - | $3.88 M(+12.3%) | $14.31 M(+0.5%) |
| June 2019 | - | $3.46 M(-2.2%) | $14.24 M(-25.1%) |
| Mar 2019 | - | $3.53 M(+2.7%) | $19.02 M(-7.6%) |
| Dec 2018 | $20.58 M | $3.44 M(-9.7%) | $20.58 M(+4.1%) |
| Sept 2018 | - | $3.81 M(-53.7%) | $19.77 M(+5.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | $8.23 M(+61.5%) | $18.81 M(+61.7%) |
| Mar 2018 | - | $5.10 M(+93.5%) | $11.64 M(+50.8%) |
| Dec 2017 | $7.57 M(+119.6%) | $2.63 M(-7.4%) | $7.72 M(+73.0%) |
| Sept 2017 | - | $2.85 M(+169.0%) | $4.46 M(+57.9%) |
| June 2017 | - | $1.06 M(-10.3%) | $2.83 M(-10.9%) |
| Mar 2017 | - | $1.18 M(-289.4%) | $3.17 M(-8.1%) |
| Dec 2016 | $3.45 M(+34.0%) | -$623.00 K(-151.4%) | $3.45 M(+15.8%) |
| Sept 2016 | - | $1.21 M(-13.6%) | $2.98 M(+1.2%) |
| June 2016 | - | $1.40 M(-3.8%) | $2.94 M(+7.3%) |
| Mar 2016 | - | $1.46 M(-233.4%) | $2.74 M(+6.6%) |
| Dec 2015 | $2.57 M(-55.9%) | -$1.09 M(-192.9%) | $2.57 M(-49.6%) |
| Sept 2015 | - | $1.18 M(-2.2%) | $5.10 M(-1.7%) |
| June 2015 | - | $1.20 M(-6.7%) | $5.19 M(-2.7%) |
| Mar 2015 | - | $1.29 M(-10.2%) | $5.34 M(-8.6%) |
| Dec 2014 | $5.84 M(+81.1%) | $1.44 M(+13.4%) | $5.84 M(+7.3%) |
| Sept 2014 | - | $1.27 M(-6.1%) | $5.44 M(+3.8%) |
| June 2014 | - | $1.35 M(-24.7%) | $5.25 M(+9.9%) |
| Mar 2014 | - | $1.79 M(+71.9%) | $4.77 M(+48.1%) |
| Dec 2013 | $3.22 M(+372.0%) | $1.04 M(-2.6%) | $3.22 M(+36.3%) |
| Sept 2013 | - | $1.07 M(+22.2%) | $2.37 M(+64.1%) |
| June 2013 | - | $875.00 K(+266.1%) | $1.44 M(+88.6%) |
| Mar 2013 | - | $239.00 K(+31.3%) | $764.00 K(+45.5%) |
| Dec 2012 | $683.00 K(-67.2%) | $182.00 K(+25.5%) | $525.00 K(+53.1%) |
| Sept 2012 | - | $145.00 K(-26.8%) | $343.00 K(+73.2%) |
| June 2012 | - | $198.00 K | $198.00 K |
| Dec 2011 | $2.08 M | - | - |
FAQ
- What is Arcturus Therapeutics Holdings annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings annual SG&A year-on-year change?
- What is Arcturus Therapeutics Holdings quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings quarterly SG&A year-on-year change?
- What is Arcturus Therapeutics Holdings TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings TTM SG&A year-on-year change?
What is Arcturus Therapeutics Holdings annual selling, general & administrative expenses?
The current annual SG&A of ARCT is $52.87 M
What is the all time high annual SG&A for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high annual selling, general & administrative expenses is $52.87 M
What is Arcturus Therapeutics Holdings annual SG&A year-on-year change?
Over the past year, ARCT annual selling, general & administrative expenses has changed by +$6.80 M (+14.76%)
What is Arcturus Therapeutics Holdings quarterly selling, general & administrative expenses?
The current quarterly SG&A of ARCT is $13.28 M
What is the all time high quarterly SG&A for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high quarterly selling, general & administrative expenses is $14.85 M
What is Arcturus Therapeutics Holdings quarterly SG&A year-on-year change?
Over the past year, ARCT quarterly selling, general & administrative expenses has changed by -$101.00 K (-0.76%)
What is Arcturus Therapeutics Holdings TTM selling, general & administrative expenses?
The current TTM SG&A of ARCT is -$1.59 B
What is the all time high TTM SG&A for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high TTM selling, general & administrative expenses is $53.96 M
What is Arcturus Therapeutics Holdings TTM SG&A year-on-year change?
Over the past year, ARCT TTM selling, general & administrative expenses has changed by -$1.65 B (-3150.80%)